Copyright © 1999 by the European Society of Cardiology.
Increasing the impact of cardiological treatments. How best to reduce deaths
a Department of Public Health, University of Glasgow, Glasgow, Scotland, U.K.
c The Clinical Research Initiative in Heart Failure, University of Glasgow, Glasgow, Scotland, U.K.
b Department of Public Health, Greater Glasgow Health Board, Glasgow, Scotland, U.K.
revised April 4, 1999; accepted April 7, 1999 1999
Abstract
Aims To determine the extent to which increases in the uptake of effective treatments could further reduce coronary heart disease mortality in Scotland.
Methods and Results A cohort-based mortality model combining effectiveness data from published meta-analyses with available information on uptake of all coronary heart disease treatments in all patient categories in Scotland (population 5·1 million). In 1994, medical and surgical coronary disease treatments prevented or postponed an estimated 2722 deaths (minimum estimate 1373, maximum estimate 5986). Increasing treatment uptake to 100% of all eligible patients was considered unrealistic. Increasing uptake to 80% would have prevented or postponed a further 4078 deaths (39% from increases in secondary prevention therapies, 29%, 13%, 10% and 9% from the treatments of heart failure, acute myocardial infarction, hypertension and angina respectively).
Conclusions Many eligible patients are currently not receiving treatment that is effective in reducing coronary heart disease mortality. Increasing treatment uptake could prevent or postpone a further 4080 deaths each year in Scotland, approximately, more than doubling the present benefit from treatment. By implication, about 30000 additional deaths could be prevented, annually, in the U.K. Comparable symptom and morbidity benefits might also be expected. Future clinical audit activities should focus particularly on secondary prevention and heart failure treatments.
Key Words: Mortality, cardiology, treatment, audit coronary heart disease
f1 Correspondence: Dr Simon Capewell, University of Glasgow, Department of Public Health, 1 Lilybank Gardens, Glasgow G12 8RZ, Scotland.
References
- Coronary Disease Statistics. London: British Heart Foundation; 1998.
- Collins R, Peto R, MacMahon S. Blood pressure, stroke and coronary heart disease. Part 2, Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827–838[CrossRef][Web of Science][Medline]
- Altman R, Carreras L, Diaz R. Collaborative overview of randomised trials of antiplatelet therapy-1 Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81–106
[Abstract/Free Full Text] - Appleby P, Baigent C, Collins R. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311–322[CrossRef][Web of Science][Medline]
- Garg R, Yusuf S. Overview of randomized trails of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450–1456
[Abstract/Free Full Text] - Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389[CrossRef][Web of Science][Medline]
- Lau J, Antman EM, Jiminez-Silva J. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Eng J Med. 1992;327:248–254[Abstract]
- Collins R, Baigent C, Peto R. Benefit of Heparin plus Aspirin versus aspirin alone in unstable angina. JAMA. 1996;276:1873
[Abstract/Free Full Text] - Yusuf S, Zucker D, Peduzzi P. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563–570[CrossRef][Web of Science][Medline]
- Pocock SJ, Henderson RA, Rickards AF. Meta analysis of randomized trials comparing coronary angioplasty with bypass-surgery. Lancet. 1995;346:1184–1189[CrossRef][Web of Science][Medline]
- Vantrimpont P, Rouleau JL, Wun CC. Additive beneficial effects of beta blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol. 1997;29:229–236[Abstract]
- Teasdale S. The future of clinical audit: learning to work together. Br Med J. 1996;313:574–575
[Free Full Text] - Capewell S, Gailey F, Fisher A, Parker S, McDonald I, Padfield PL. Audit of myocardial infarction management in South East Scotland. H Bulletin. 1997;55:399–407
- Eur Heart J. 1997;18:1569–1582
[Abstract/Free Full Text] - French JK, Williams BF, Hart HH. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med J. 1996;312:1637–1641
[Abstract/Free Full Text] - Bowker TJ, Clayton TC, Ingham J. A British Cardiac Society Survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart. 1996;75:334–342
[Abstract/Free Full Text] - Eccles M, Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England. Br Med J. 1991;302:91–92
[Abstract/Free Full Text] - Whitford DL, Southern AJ. Audit of secondary prophylaxis after myocardial infarction. Br Med J. 1994;309:1268–1269
[Free Full Text] - McCallum AK, Whincup PH, Morris RW, Thomson A, Walker M, Ebrahim S. Aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed. Br J Gen Pract. 1997;47:417–421[Web of Science][Medline]
- Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart-failure. Br Heart J. 1994;71:584–587
[Abstract/Free Full Text] - Hillis GS, Trent RJ, Winton P, Macleod AM, Jennings KP. Angiotensin-Converting-Enzyme inhibitors in the management of cardiac-failure—are we ignoring the evidence. Monthly J Ass Phys. 1996;89:145–150
- Capewell S, Morrison C, McMurray J. Contribution of modern cardiovascular treatment to the decline in coronary heart disease mortality in Scotland between 1975 and 1995. Heart. 1999;81:380–387
[Abstract/Free Full Text] - Smith WCS, Lee AJ, Crombie IK, Tunstall-Pedoe H. Control of blood pressure in Scotland: the rule of halves. Br Med J. 1990;300:981–983
[Abstract/Free Full Text] - Public Health Policy Unit, Scottish Office Dept of Health, Coronary Heart Disease in Scotland: Report of a Policy Review, London, HMSO
- Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Economics. 1994;3:95–104[Web of Science][Medline]
- Robinson MB, Thompson E, Black NA. Evaluation of the effectiveness of guidelines, audit and feedback: improving the use of intravenous thrombolysis in patients with suspected acute myocardial infarction. Int J Quality in H Care. 1996;3:211–222
- Currie P, Gray SM, Shaw TRD, Starkey IR. Success of audit in reducing the time taken to administer thrombolysis and aspirin in patients with acute myocardial infarction. Scot Med J. 1994;39:120–122
- Weston CFM, Penny WJ, Julian DG. Guidelines for the early management of patients with myocardial infarction. Br Med J. 1994;308:767–771
[Free Full Text] - Thompson DR, Bowman GS, Kitson AL, De Bono DP, Hopkins A. Cardiac rehabilitation in the United Kingdom: guidelines and audit standards. Heart. 1996;75:89–93
[Abstract/Free Full Text] - Rihal CS, Yusuf S. Chronic coronary artery disease: drugs, angioplasty or surgery. Br Med J. 1996;312:265–266
[Free Full Text] - Ioannidis JPA, Lau J. The impact of high risk patients on the population risk and on the population tretment effect. J Clin Epidemiol. 1997;50:1089–1098[CrossRef][Web of Science][Medline]
- Mant J, Hicks N. Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. Br Med J. 1995;311:793–796
[Free Full Text] - Mullen PD. Compliance becomes concordance. Br Med J. 1997;314:691–692
[Free Full Text] - Hunink MGM, Goldman L, Tosteson ANA. The recent decline in mortality from coronary heart disease, 1980–1990: the effect of secular trends in risk factors and treatment. J Am Med Ass. 1997;277:535–542
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N F Murphy, S Stewart, C L Hart, K MacIntyre, D Hole, and J J V McMurray A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew-Paisley study Heart, December 1, 2006; 92(12): 1739 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Kabir, K. Bennett, E. Shelley, B. Unal, J. Critchley, J. Feely, and S. Capewell The population mortality benefits of maximizing the number of eligible patients receiving appropriate cardiology treatments in Ireland QJM, August 1, 2006; 99(8): 523 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bennett, Z. Kabir, B. Unal, E. Shelley, J. Critchley, I. Perry, J. Feely, and S. Capewell Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000. J Epidemiol Community Health, April 1, 2006; 60(4): 322 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Laatikainen, J. Critchley, E. Vartiainen, V. Salomaa, M. Ketonen, and S. Capewell Explaining the Decline in Coronary Heart Disease Mortality in Finland between 1982 and 1997 Am. J. Epidemiol., October 15, 2005; 162(8): 764 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Unal, J. A. Critchley, and S. Capewell Explaining the Decline in Coronary Heart Disease Mortality in England and Wales Between 1981 and 2000 Circulation, March 9, 2004; 109(9): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J A Critchley and S Capewell Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels J Epidemiol Community Health, April 1, 2003; 57(4): 243 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.A. Critchley and S. Capewell Why model coronary heart disease? Eur. Heart J., January 2, 2002; 23(2): 110 - 116. [Full Text] [PDF]
|
|
|
|
|
|
H.M. Krumholz Gaps and opportunities in the practice of medicine: the need for improved systems of care Eur. Heart J., June 1, 2001; 22(11): 889 - 890. [PDF]
|
|
|
|
|
|
C Hengstenberg, S.R Holmer, B Mayer, S Engel, A Schneider, H Lowel, G.A.J Riegger, and H Schunkert Siblings of myocardial infarction patients are overlooked in primary prevention of cardiovascular disease Eur. Heart J., June 1, 2001; 22(11): 926 - 933. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Z. Ayanian and T. J. Quinn Quality Of Care For Coronary Heart Disease In Two Countries Health Aff., May 1, 2001; 20(3): 55 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Capewell, R. Beaglehole, M. Seddon, and J. McMurray Explanation for the Decline in Coronary Heart Disease Mortality Rates in Auckland, New Zealand, Between 1982 and 1993 Circulation, September 26, 2000; 102(13): 1511 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. CAPEWELL and J. MCMURRAY Coronary heart disease trends in France and elsewhere Heart, August 1, 2000; 84(2): 121 - 122. [Full Text] [PDF]
|
|
|
|
|
|
H. Rosolova and J. Simon Editorials: Potential to reduce death by cardiological treatment Eur. Heart J., October 1, 1999; 20(19): 1376 - 1377. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||